2022
Early Surgery for Patients With Asymptomatic Severe Aortic Stenosis: A Meta-Analysis of Randomized Controlled Trials
Ahmad Y, Howard J, Seligman H, Arnold A, Madhavan M, Forrest J, Geirsson A, Mack M, Lansky A, Leon M. Early Surgery for Patients With Asymptomatic Severe Aortic Stenosis: A Meta-Analysis of Randomized Controlled Trials. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100383. PMID: 39131941, PMCID: PMC11307849, DOI: 10.1016/j.jscai.2022.100383.Peer-Reviewed Original ResearchSurgical aortic valve replacementAsymptomatic severe aortic stenosisSevere aortic stenosisAortic stenosisHF hospitalizationCause mortalityEjection fractionPrespecified primary end pointSevere asymptomatic aortic stenosisSymptomatic severe aortic stenosisEnd pointAortic valve interventionAsymptomatic aortic stenosisHeart failure hospitalizationPrimary end pointAortic valve replacementClass I recommendationCornerstone of managementInitial conservative managementNormal ejection fractionRandomized Controlled TrialsCurrent treatment standardsIndividual end pointsAsymptomatic patientsEarly surgeryPCI in Patients With Heart Failure: Current Evidence, Impact of Complete Revascularization, and Contemporary Techniques to Improve Outcomes
Ahmad Y, Petrie M, Jolicoeur E, Madhavan M, Velazquez E, Moses J, Lansky A, Stone G. PCI in Patients With Heart Failure: Current Evidence, Impact of Complete Revascularization, and Contemporary Techniques to Improve Outcomes. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100020. PMID: 39132568, PMCID: PMC11307477, DOI: 10.1016/j.jscai.2022.100020.Peer-Reviewed Original ResearchPercutaneous coronary interventionLeft ventricular systolic dysfunctionCoronary artery diseaseHeart failureComplete revascularizationMedical therapyClinical outcomesClinical trialsCoronary artery bypassVentricular systolic dysfunctionClinical trial evidenceHigh operative riskHigh-risk patientsMajor cardiac surgeryExtent of revascularizationMinority of patientsFuture clinical trialsArtery bypassCause mortalityPeriprocedural complicationsSystolic dysfunctionCoronary interventionOperative riskArtery diseaseCardiac surgeryImproved outcomes in patients with severely depressed LVEF undergoing percutaneous coronary intervention with contemporary practices
O'Neill WW, Anderson M, Burkhoff D, Grines CL, Kapur NK, Lansky AJ, Mannino S, McCabe JM, Alaswad K, Daggubati R, Wohns D, Meraj PM, Pinto DS, Popma JJ, Moses JW, Schreiber TL, Ohman E. Improved outcomes in patients with severely depressed LVEF undergoing percutaneous coronary intervention with contemporary practices. American Heart Journal 2022, 248: 139-149. PMID: 35192839, DOI: 10.1016/j.ahj.2022.02.006.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionHigh-risk percutaneous coronary interventionPROTECT IIProTECT IIICoronary interventionDepressed LVEFIII studyIII patientsMyocardial infarctionStroke/transient ischemic attackTransient ischemic attackCompleteness of revascularizationPrior myocardial infarctionKaplan-Meier analysisDuration of supportHospital bleedingMACCE rateProcedural hypotensionCause mortalityCerebrovascular eventsIschemic attackJeopardy scorePrior CABGSYNTAX scoreHospital discharge
2021
The influence of biological age and sex on long-term outcome after percutaneous coronary intervention for ST-elevation myocardial infarction.
Rathod KS, Jones DA, Jain AK, Lim P, MacCarthy PA, Rakhit R, Lockie T, Kalra S, Dalby MC, Malik IS, Whitbread M, Firoozi S, Bogle R, Redwood S, Cooper J, Gupta A, Lansky A, Wragg A, Mathur A, Ahluwalia A. The influence of biological age and sex on long-term outcome after percutaneous coronary intervention for ST-elevation myocardial infarction. Am J Cardiovasc Dis 2021, 11: 659-678. PMID: 34849299, PMCID: PMC8611266.Peer-Reviewed Original ResearchST-segment elevation myocardial infarctionCause mortalityFemale sexCox analysisMyocardial infarctionST-elevation myocardial infarctionAge-matched menObservational cohort studyElevation myocardial infarctionPercutaneous coronary interventionKaplan-Meier analysisLong-term outcomesProportional hazards modelSub-group analysisHigh mortality rateYears of agePost-PCIPrimary PCICoronary interventionSTEMI patientsCohort studyMultivariate adjustmentPrimary outcomeUnivariate predictorsMenopausal yearsCardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis
Navarese EP, Lansky AJ, Kereiakes DJ, Kubica J, Gurbel PA, Gorog DA, Valgimigli M, Curzen N, Kandzari DE, Bonaca MP, Brouwer M, Umińska J, Jaguszewski MJ, Raggi P, Waksman R, Leon MB, Wijns W, Andreotti F. Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. European Heart Journal 2021, 42: 4638-4651. PMID: 34002203, PMCID: PMC8669551, DOI: 10.1093/eurheartj/ehab246.Peer-Reviewed Original ResearchConceptsSpontaneous myocardial infarctionStable coronary artery disease patientsCoronary artery disease patientsElective coronary revascularisationMedical therapyCardiac mortalityMyocardial infarctionCoronary revascularisationCause mortalityDisease patientsPre-specified primary endpointCoronary artery diseaseRate ratioDeath risk reductionRandom-effects modelMultivessel diseaseMortality findingsPrimary endpointSecondary endpointsStable patientsStroke riskSurvival benefitArtery diseaseCardiac deathRevascularisationA randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial
Lansky AJ, Makkar R, Nazif T, Messé S, Forrest J, Sharma R, Schofer J, Linke A, Brown D, Dhoble A, Horwitz P, Zang M, DeMarco F, Rajagopal V, Dwyer MG, Zivadinov R, Stella P, Rovin J, Parise H, Kodali S, Baumbach A, Moses J. A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial. European Heart Journal 2021, 42: 2670-2679. PMID: 34000004, DOI: 10.1093/eurheartj/ehab213.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementEfficacy endpointCerebral embolic protection devicesTranscatheter aortic valve implantationCentral nervous system injuryCerebral embolic lesionsCerebral ischemic lesionsHealth Stroke ScalePrimary efficacy endpointPrimary safety outcomeAortic valve replacementAortic valve implantationEmbolic protection devicesNervous system injuryDiffusion-weighted magnetic resonanceMontreal Cognitive AssessmentEffectiveness endpointCause mortalityCerebral protectionSafety endpointStroke ScaleValve implantationValve replacementI trialIschemic lesions
2020
Survival After Coronary Revascularization With Paclitaxel-Coated Balloons
Scheller B, Vukadinovic D, Jeger R, Rissanen TT, Scholz SS, Byrne R, Kleber FX, Latib A, Clever YP, Ewen S, Böhm M, Yang Y, Lansky A, Mahfoud F. Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. Journal Of The American College Of Cardiology 2020, 75: 1017-1028. PMID: 32138961, DOI: 10.1016/j.jacc.2019.11.065.Peer-Reviewed Original ResearchConceptsDrug-coated balloonsPaclitaxel-coated balloonRisk of deathCause mortalityRisk ratioStent restenosisPaclitaxel drug-coated balloonPaclitaxel-coated devicesDe novo lesionsCoronary artery diseaseSuperficial femoral arteryCochrane Library databasesConfidence intervalsNumber of patientsWeb of ScienceCardiac mortalityCoronary revascularizationNovo lesionsCoronary interventionDCB groupDifferent time pointsArtery diseasePrimary outcomeFemoral arteryPeripheral arteries
2018
Sex disparities in acute myocardial infarction care and outcomes
Gul B, Kozuma K, Haimi I, Zhao W, Simonton C, Ying S, Buda A, Mehta S, Baumbach A, Lansky A. Sex disparities in acute myocardial infarction care and outcomes. Catheterization And Cardiovascular Interventions 2018, 92: e341-e347. PMID: 29745453, DOI: 10.1002/ccd.27622.Peer-Reviewed Original ResearchMeSH KeywordsAgedChinaClinical Trials as TopicFemaleHealthcare DisparitiesHemorrhageHumansJapanMaleMiddle AgedNon-ST Elevated Myocardial InfarctionPercutaneous Coronary InterventionProduct Surveillance, PostmarketingRegistriesRetrospective StudiesRisk AssessmentRisk FactorsSex FactorsST Elevation Myocardial InfarctionStentsTime FactorsTreatment OutcomeUnited StatesConceptsMajor adverse cardiac eventsAcute myocardial infarctionPercutaneous coronary interventionTarget vessel failureCause mortalityXience V stentMajor bleedingUS patientsHigher major adverse cardiac eventsSetting of AMIContemporary percutaneous coronary interventionAcute myocardial infarction careDevice-specific outcomesAdverse cardiac eventsMyocardial infarction carePost-market registryCause deathCardiac eventsCoronary interventionMultivariable analysisFemale sexMyocardial infarctionPatient levelSex disparitiesPatientsA prospective, multi‐center study of the chocolate balloon in femoropopliteal peripheral artery disease: The Chocolate BAR registry
Mustapha JA, Lansky A, Shishehbor M, McClure J, Johnson S, Davis T, Makam P, Crowder W, Konstantino E, Attaran RR, Investigators T. A prospective, multi‐center study of the chocolate balloon in femoropopliteal peripheral artery disease: The Chocolate BAR registry. Catheterization And Cardiovascular Interventions 2018, 91: 1144-1148. PMID: 29513389, DOI: 10.1002/ccd.27565.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, BalloonEquipment DesignFemaleFemoral ArteryHumansMaleMiddle AgedPeripheral Arterial DiseasePopliteal ArteryProduct Surveillance, PostmarketingProspective StudiesRegistriesRisk FactorsStentsTime FactorsTreatment OutcomeUnited StatesVascular Access DevicesVascular PatencyConceptsTarget lesion revascularizationPrimary endpointFemoropopliteal peripheral artery diseaseSymptomatic peripheral arterial diseaseExcellent procedural outcomesLower dissection ratePeripheral arterial diseasePeripheral artery diseaseAcute procedural successLong-term outcomesPost-market registryMulti-center studyAngioplasty balloon catheterPercutaneous transluminal angioplasty balloon catheterRutherford classCause mortalityLesion revascularizationMajor amputationArtery diseaseArterial diseaseProcedural successUnplanned amputationBalloon catheterProcedural outcomesProcedure success
2016
Transcatheter Aortic Valve Replacement in Women Versus Men (from the US CoreValve Trials)
Forrest JK, Adams DH, Popma JJ, Reardon MJ, Deeb GM, Yakubov SJ, Hermiller JB, Huang J, Skelding KA, Lansky A. Transcatheter Aortic Valve Replacement in Women Versus Men (from the US CoreValve Trials). The American Journal Of Cardiology 2016, 118: 396-402. PMID: 27346591, DOI: 10.1016/j.amjcard.2016.05.013.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic Valve StenosisCause of DeathComorbidityFemaleFrail ElderlyHumansIncidenceMaleMortalityPostoperative ComplicationsPostoperative HemorrhageSeverity of Illness IndexSex FactorsStrokeTranscatheter Aortic Valve ReplacementTreatment OutcomeVentricular Dysfunction, LeftConceptsTranscatheter aortic valve replacementAortic valve replacementCoreValve prosthesisValve replacementSevere symptomatic aortic stenosisSurgical aortic valve replacementLeft ventricular systolic functionWomen Versus MenMajor vascular complicationsSymptomatic aortic stenosisIncidence of strokeProcedure-related complicationsVentricular systolic functionCoronary artery diseaseLife-threatening bleedsSignificant baseline differencesGender-related differencesCause mortalityVascular complicationsBaseline characteristicsPatient characteristicsPrevious strokeSystolic functionAortic stenosisArtery diseaseSafety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials
Giustino G, Mehran R, Bansilal S, Feit F, Lincoff M, Deliargyris EN, Kirtane AJ, Généreux P, Redfors B, Prats J, Bernstein D, Brener SJ, Skerjanec S, Lansky AJ, Francese DP, Dangas GD, Stone GW. Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. The American Journal Of Cardiology 2016, 118: 6-16. PMID: 27181566, DOI: 10.1016/j.amjcard.2016.04.005.Peer-Reviewed Original ResearchConceptsGlycoprotein IIb/IIIa inhibitorsPercutaneous coronary interventionMajor adverse cardiac eventsEfficacy of bivalirudinAdverse cardiac eventsDiabetes mellitusMajor bleedingCoronary interventionBivalirudin treatmentCause mortalityCardiac eventsNon-coronary artery bypass graft-related major bleedingPrimary efficacy end pointPrimary safety end pointUrgent Intervention Triage StrategyAcute Myocardial Infarction trialIIb/IIIa inhibitorsEnd pointHORIZONS-AMI trialPCI Linking AngiomaxComposite of deathEfficacy end pointMyocardial Infarction trialSafety end pointPatient-level data
2013
Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease Final 3-Year Results of the SPIRIT Clinical Trials Program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)
Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW. Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease Final 3-Year Results of the SPIRIT Clinical Trials Program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovascular Interventions 2013, 6: 914-922. PMID: 24050859, DOI: 10.1016/j.jcin.2013.05.005.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular AgentsCoronary Artery DiseaseCoronary RestenosisCoronary ThrombosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMulticenter Studies as TopicMultivariate AnalysisMyocardial InfarctionPaclitaxelPercutaneous Coronary InterventionProportional Hazards ModelsProsthesis DesignRandomized Controlled Trials as TopicRisk FactorsSirolimusTime FactorsTreatment OutcomeConceptsPaclitaxel-eluting stentsIschemia-driven target lesion revascularizationMajor adverse cardiac eventsAdverse cardiac eventsTarget lesion revascularizationLesion failureMyocardial infarctionLesion revascularizationCause mortalityCardiac eventsStent thrombosisStent typeEvent ratesTarget lesion failureClinical trial programException of diabetesIndividual patient dataIndividual clinical outcomesCardiac deathComposite endpointClinical outcomesSPIRIT IIClinical trialsCoronary implantationTrial program
2011
The impact of the coronary collateral circulation on mortality: a meta-analysis
Meier P, Hemingway H, Lansky AJ, Knapp G, Pitt B, Seiler C. The impact of the coronary collateral circulation on mortality: a meta-analysis. European Heart Journal 2011, 33: 614-621. PMID: 21969521, DOI: 10.1093/eurheartj/ehr308.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseStable coronary artery diseaseCoronary collateral circulationMyocardial infarctionCollateral circulationRisk ratioHigh collateralizationLow collateralizationSummary risk ratiosAcute myocardial infarctionSubacute myocardial infarctionRandom-effects modelRelevant protective effectCause mortalityCoronary collateralsHard endpointsArtery diseaseCoronary collateralizationVentricular remodellingInfarct sizeClinical endpointsBlood supplyProtective effectMortality riskPatientsPrognostic Impact of Staged Versus “One-Time” Multivessel Percutaneous Intervention in Acute Myocardial Infarction Analysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Kornowski R, Mehran R, Dangas G, Nikolsky E, Assali A, Claessen BE, Gersh BJ, Wong SC, Witzenbichler B, Guagliumi G, Dudek D, Fahy M, Lansky AJ, Stone GW, Investigators H. Prognostic Impact of Staged Versus “One-Time” Multivessel Percutaneous Intervention in Acute Myocardial Infarction Analysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. Journal Of The American College Of Cardiology 2011, 58: 704-711. PMID: 21816305, DOI: 10.1016/j.jacc.2011.02.071.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionMultivessel primary percutaneous coronary interventionMajor adverse cardiovascular eventsHORIZONS-AMI trialAdverse cardiovascular eventsMultivessel diseaseNonculprit lesionsCardiovascular eventsStent thrombosisPCI strategyPrimary PCIAcute Myocardial Infarction AnalysisProbable stent thrombosisTarget vessel revascularizationElevation myocardial infarctionPercutaneous coronary interventionSubgroup of patientsPrimary PCI proceduresMultivessel percutaneous interventionNonculprit vesselsCardiac mortalityCause mortalityCulprit lesionSTEMI patientsPredictors and Implications of Coronary Infarct Artery Patency at Initial Angiography in Patients With Acute Myocardial Infarction (from the CADILLAC and HORIZONS-AMI Trials)
Brener SJ, Mehran R, Brodie BR, Guagliumi G, Witzenbichler B, Cristea E, Xu K, Lansky AJ, Stone GW. Predictors and Implications of Coronary Infarct Artery Patency at Initial Angiography in Patients With Acute Myocardial Infarction (from the CADILLAC and HORIZONS-AMI Trials). The American Journal Of Cardiology 2011, 108: 918-923. PMID: 21764028, DOI: 10.1016/j.amjcard.2011.05.022.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCoronary AngiographyCoronary CirculationCoronary VesselsDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPredictive Value of TestsRegional Blood FlowVascular PatencyConceptsTIMI grade 3 flowGrade 3 flowFinal TIMI grade 3 flowST-segment elevation myocardial infarctionElevation myocardial infarctionIndependent predictorsMyocardial infarctionPre-percutaneous coronary intervention (PCI) thrombolysisMyocardial Infarction (TIMI) grade 3 flowAcute Myocardial Infarction trialExtensive coronary diseaseLate Angioplasty ComplicationsMyocardial Infarction trialInfarct artery patencyAcute myocardial infarctionSignificant independent predictorsHigh-risk characteristicsAngioplasty complicationsBaseline TIMIControlled AbciximabHarmonizing OutcomesInitial angiographyCause mortalityPrimary PCIArtery patencyImpact of Leukocyte Count on Mortality and Bleeding in Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Interventions
Palmerini T, Mehran R, Dangas G, Nikolsky E, Witzenbichler B, Guagliumi G, Dudek D, Genereux P, Caixeta A, Rabbani L, Weisz G, Parise H, Fahy M, Xu K, Brodie B, Lansky A, Stone GW. Impact of Leukocyte Count on Mortality and Bleeding in Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Interventions. Circulation 2011, 123: 2829-2837. PMID: 21632496, DOI: 10.1161/circulationaha.110.985564.Peer-Reviewed Original ResearchConceptsWhite blood cell countPeak creatinine phosphokinase levelCreatinine phosphokinase levelsPercutaneous coronary interventionST-segment elevation acute myocardial infarctionBaseline white blood cell countCoronary interventionAcute myocardial infarctionIndependent predictorsNoncardiac mortalityCardiac mortalityMyocardial infarctionMajor bleedingHigher white blood cell countLower white blood cell countPropensity-adjusted multivariable analysisAcute Myocardial Infarction trialPrimary percutaneous coronary interventionMyocardial Infarction trialVentricular ejection fractionSubgroup of patientsBlood cell countHarmonizing OutcomesCause mortalityEjection fraction
2010
Impact of Anemia on Clinical Outcomes of Patients With ST-Segment Elevation Myocardial Infarction in Relation to Gender and Adjunctive Antithrombotic Therapy (from the HORIZONS-AMI Trial)
Tsujita K, Nikolsky E, Lansky AJ, Dangas G, Fahy M, Brodie BR, Dudek D, Möckel M, Ochala A, Mehran R, Stone GW. Impact of Anemia on Clinical Outcomes of Patients With ST-Segment Elevation Myocardial Infarction in Relation to Gender and Adjunctive Antithrombotic Therapy (from the HORIZONS-AMI Trial). The American Journal Of Cardiology 2010, 105: 1385-1394. PMID: 20451683, DOI: 10.1016/j.amjcard.2010.01.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnemiaAngioplasty, Balloon, CoronaryCombined Modality TherapyDrug Therapy, CombinationElectrocardiographyFemaleFibrinolytic AgentsFollow-Up StudiesHeparinHirudinsHospital MortalityHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionNeoadjuvant TherapyPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProbabilityProportional Hazards ModelsRecombinant ProteinsRisk AssessmentSex FactorsSurvival AnalysisThrombolytic TherapyTreatment OutcomeConceptsST-elevation myocardial infarctionElevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBaseline anemiaPercutaneous coronary interventionAdjunctive antithrombotic therapyMajor bleedingMyocardial infarctionAntithrombotic therapyCoronary interventionUnfractionated heparinST-segment elevation myocardial infarctionMultivariate analysisAcute Myocardial Infarction trialImpact of anemiaMyocardial Infarction trialOutcomes of patientsHarmonizing OutcomesCardiac mortalityCause mortalityLate mortalityPrimary PCIClinical outcomes
2009
Gastrointestinal Bleeding in Patients With Acute Coronary Syndromes: Incidence, Predictors, and Clinical Implications Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial
Nikolsky E, Stone GW, Kirtane AJ, Dangas GD, Lansky AJ, McLaurin B, Lincoff AM, Feit F, Moses JW, Fahy M, Manoukian SV, White HD, Ohman EM, Bertrand ME, Cox DA, Mehran R. Gastrointestinal Bleeding in Patients With Acute Coronary Syndromes: Incidence, Predictors, and Clinical Implications Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. Journal Of The American College Of Cardiology 2009, 54: 1293-1302. PMID: 19778672, DOI: 10.1016/j.jacc.2009.07.019.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAge FactorsAgedAngioplasty, Balloon, CoronaryAnticoagulantsClopidogrelCoronary Artery BypassFemaleGastrointestinal HemorrhageHeparinHirudinsHumansIncidenceIschemiaLength of StayMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsRisk AssessmentSex FactorsStentsThrombosisTiclopidineConceptsAcute coronary syndromeGastrointestinal bleedingACUITY trialComposite ischemiaCardiac mortalityCause mortalityCoronary syndromeHigh-risk acute coronary syndromesStudy drug administrationOpen-label usePotential hemorrhagic complicationsST-segment deviationAntiplatelet medicationsBaseline anemiaHemorrhagic complicationsIschemic complicationsIndependent predictorsClinical outcomesMultivariable analysisStent thrombosisMyocardial infarctionSerious conditionPatientsDrug AdministrationOlder age
2005
Impact of In-Hospital Acquired Thrombocytopenia in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction
Nikolsky E, Sadeghi HM, Effron MB, Mehran R, Lansky AJ, Na Y, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, Turco M, Carroll JD, Grines CL, Stone GW. Impact of In-Hospital Acquired Thrombocytopenia in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction. The American Journal Of Cardiology 2005, 96: 474-481. PMID: 16098296, DOI: 10.1016/j.amjcard.2005.04.005.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAge DistributionAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCause of DeathFemaleFollow-Up StudiesHemorrhageHumansImmunoglobulin Fab FragmentsIncidenceInpatientsMaleMiddle AgedMyocardial InfarctionOdds RatioPlatelet Aggregation InhibitorsPlatelet CountProspective StudiesRisk FactorsSex DistributionSurvival RateThrombocytopeniaTreatment OutcomeConceptsPrimary percutaneous coronary interventionPercutaneous coronary interventionAcute myocardial infarctionHemorrhagic complicationsAcquired thrombocytopeniaPlatelet countMyocardial infarctionHigher baseline platelet countGreater body mass indexNadir platelet countPrevious aspirin useUse of abciximabBaseline platelet countBlood product transfusionLonger hospital stayMajor hemorrhagic complicationsHours of onsetBody mass indexAspirin useBaseline thrombocytopeniaCADILLAC trialIschemic complicationsCause mortalityHospital stayPrimary angioplasty